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Abstract
HIV pre-exposure prophylaxis (PrEP) is dominated by clinical therapeutic antiretroviral
(ARV) drugs. Griffithsin (GRFT) is a non-ARV lectin with potent anti-HIV activity. GRFT’s
preclinical safety, lack of systemic absorption after vaginal administration in animal studies,
and lack of cross-resistance with existing ARV drugs prompted its development for topical
HIV PrEP. We investigated safety, pharmacokinetics (PK), pharmacodynamics (PD), and
immunogenicity of PC-6500 (0.1% GRFT in a carrageenan (CG) gel) in healthy women after
vaginal administration. This randomized, placebo-controlled, parallel group, double-blind
first-in-human phase 1 study enrolled healthy, HIV-negative, non-pregnant women aged
24–45 years. In the open label period, all participants (n = 7) received single dose of PC6500. In the randomized period, participants (n = 13) were instructed to self-administer 14
doses of PC-6500 or its matching CG placebo (PC-535) once daily for 14 days. The primary
outcomes were safety and PK after single dose, and then after 14 days of dosing. Exploratory outcomes were GRFT concentrations in cervicovaginal fluids, PD, inflammatory mediators and gene expression in ectocervical biopsies. This trial is registered with ClinicalTrials.
gov, number NCT02875119. No significant adverse events were recorded in clinical or laboratory results or histopathological evaluations in cervicovaginal mucosa, and no anti-drug
(GRFT) antibodies were detected in serum. No cervicovaginal proinflammatory responses
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and no changes in the ectocervical transcriptome were evident. Decreased levels of proinflammatory chemokines (CXCL8, CCL5 and CCL20) were observed. GRFT was not
detected in plasma. GRFT and GRFT/CG in cervicovaginal lavage samples inhibited HIV
and HPV, respectively, in vitro in a dose-dependent fashion. These data suggest GRFT formulated in a CG gel is a safe and promising on-demand multipurpose prevention technology
product that warrants further investigation.

Introduction
HIV continues to be a major global public health issue, ranking as the leading cause of death
in women aged 15–44 worldwide. In 2019, an estimated 38 million people globally were living
with HIV [1]. Young women aged 15–24 are especially at risk, with approximately 5500 new
infections each week worldwide [1]. In sub-Saharan Africa, five in six new infections among
adolescents aged 15–19 years are among girls, and young women aged 15–24 years are twice as
likely to be living with HIV than men of the same age [1].
Currently, once daily oral Truvada (tenofovir disoproxil fumarate-emtricitabine [TDF/
FTC]) is the only product for HIV pre-exposure prophylaxis (PrEP) approved by the Food and
Drug Administration (FDA) for cisgender women. Approval was based on the results of clinical trials demonstrating significantly reduced risk of HIV acquisition in cisgender men and
transgender women who have sex with men (iPrEX) and in serodiscordant couples (Partners
PrEP Study) [2, 3]. Truvada was shown to be efficacious in cisgender men and transgender
women who have sex with men even if taken intermittently (STRAND) [4] or on-demand
(IPERGAY) [5]. In contrast, daily Truvada did not demonstrate efficacy in two studies in cisgender women (FEM-PrEP and VOICE) [6, 7]. Low adherence rates [6, 7] potentially explain
these results. Recent clinical trials (HPTN083 and HPTN 084) have demonstrated high efficacy
of long-acting (LA) injectable Cabotegravir against HIV acquisition which was superior to
Truvada [8, 9]. LA parenteral products (injectables and implants) could offer simpler administration regimens and may be preferred over daily oral regimens for some women. However,
these products require health care provider delivery, have injection site and potential systemic
side effects, and, for the case of implants, may not be easily removable. Alternatively, user-controlled vaginally administered PrEP (gel, fast dissolving vaginal insert (FDI), intravaginal rings
(IVR), vaginal film) offers the distinct advantage of increasing local exposure to the active
pharmaceutical ingredients (APIs) at the HIV transmission site and low to no systemic side
effects.
Studies in the US and Africa demonstrated variability in preferences for HIV prevention
products across groups and geographies and emphasized that women need options of different
routes of PrEP administration and formulations suitable for their lives [10–12]. Expanding
available PrEP options is likely to improve uptake of HIV prevention products just as contraceptive choice increased uptake, retention and contraceptive effectiveness (reviewed in [13,
14]). Therefore, it is critical to develop diverse PrEP products that align with preferences of
people at risk of HIV infection.
In addition to adherence, other factors such as drug and dosage form-related characteristics
(tenofovir distribution in colorectal tissues and female genital tissues [15]) and genital inflammation promoting susceptibility to HIV [16] may impact PrEP efficacy. Therefore, a thorough
analysis of relationships between PrEP and mucosal environment (including transcriptome
and proteome) may provide important data early in the product development process to
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identify PrEP candidates with favorable pharmacokinetics (PK) profiles across the conditions
that do not induce perturbations in the mucosa that could lead to enhanced susceptibility to
HIV and decreased PrEP efficacy.
The PrEP development pipeline has been dominated by repurposing approved therapeutic
antiretroviral (ARV) drugs [13], which are undoubtedly an important addition to the
toolbox of HIV prevention methods for women. However, a product that does not contain
ARVs (particularly those approved for HIV treatment) offers several potential advantages.
First, a product without an ARV is less likely to lead to drug-resistant HIV that may compromise subsequent ARV treatment options. Second, because the risk of resistance is low, nonARV-based products are unlikely to require labeling indicating the need for HIV testing before
and during use (once safety has been demonstrated in individuals with HIV). Removing the
need for frequent HIV testing would overcome one of the barriers cited by individuals who are
reluctant to use PrEP or who initiate PrEP and then discontinue [17–19]. Third, a non-ARVbased PrEP is likely to be approved faster by regulatory authorities as an over-the-counter
(OTC) product than one with ARVs.
The Population Council is developing griffithsin (GRFT) as topical PrEP for on-demand
use or sustained delivery. GRFT is a non-ARV lectin that has an outstanding anti-HIV activity
(50% effective concentration (EC50) of 0.13 nM, and 90% effective concentration (EC90) of
0.58 nM) [20]. Unlike the “first generation” or broad-spectrum microbicides that did not demonstrate efficacy [21–29], GRFT acts by binding to the viral gp120 glycoprotein and blocking
virus entry [30]. GRFT prevents both cell-free and cell-associated HIV transmission and
blocks virus-cell fusion [31]. GRFT also has activity against other highly prevalent and morbid
sexually transmitted infections (STIs), such as herpes simplex virus type-2 (HSV-2) and
human papillomavirus (HPV), with overlapping HIV epidemiology that increase the risk of
HIV acquisition and represent a significant public health burden in their own right [32].
GRFT inhibits HSV-2 by targeting viral entry and cell-to-cell mediated transmission [33, 34].
GRFT’s moderate activity against HPV is mediated by promoting HPV receptor internalization [34]. A GRFT multipurpose prevention technology (MPT) product that protects against
HIV, HSV and HPV would be a promising addition to products in development based on
anti-HIV and anti-HSV monoclonal antibodies [35, 36].
This report describes the results of a Phase 1 trial of PC-6500 (0.1% GRFT in a CG gel) in
healthy female volunteers conducted in the Bronx, NY. The aim of this trial (Population Council Protocol No. 728) was to gather first-in-human safety data and support further development of GRFT in various topical formulations. The primary objectives were (1) to evaluate the
safety of PC-6500 gel used vaginally for a single dose, and then once daily for 14 consecutive
days of dosing, and (2) to assess PK of GRFT in blood after a single dose, and then after 14
days of dosing. Exploratory safety and pharmacodynamics (PD) objectives included analysis of
soluble immune mediators, cervical transcriptome and anti-HIV/HPV activity of cervicovaginal secretions.

Material and methods
Trial design
A 14-day randomized, placebo-controlled, parallel group, double-blind Phase 1 trial of PC6500, sponsored by the Population Council (New York, NY), was conducted at the Albert Einstein College of Medicine (Einstein) in the Bronx, NY. The main (randomized) period of the
trial was preceded by a single-dose, open label (OL) period among a different group of participants. The protocol was approved by the Institutional Review Boards of the Population Council and Einstein prior to initiation of data collection. The protocol was submitted to the US
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Food and Drug Administration as IND # 123512 and registered at Clinical Trials.gov., number
NCT02875119. All participants provided written informed consent before undergoing any
procedures. Participants and staff at the Council and Einstein were blinded to the product
assignment for the randomized portion of the study, but not time point, through the end of
data collection.

Study population
Healthy, HIV-negative, nonpregnant women aged 18–49 who were using an effective contraceptive method other than condoms or a vaginal ring, and who agreed to remain sexually
abstinent during the study were invited to participate. Potential participants were assigned a
unique identification number and screened for eligibility based on medical history, physical
examination, pelvic examination, Pap smear if indicated, blood (CBC and chemistry) and STI
testing, including HIV, chlamydia, gonorrhea, and trichomonas. Women with a laboratory
abnormality, STI or abnormal Pap test were ineligible. Women with symptomatic BV, vulvovaginal candidiasis, or urinary tract infection at screening could be rescreened following completion of treatment.

Study products, randomization, and blinding
All participants (n = 7) in the OL period were to receive one single 4 g dose of PC-6500 administered vaginally by a study clinician.
In the randomized period, 20 participants were instructed to self-administer 14 doses of
PC-6500 or its matching CG placebo (PC-535) once daily for 14 days; OL participants were
not eligible for the randomized period to prevent participants using both PC-6500 and placebo, which could confound data interpretation. Day 1/Dose 1 was scheduled as soon as possible after menstruation ended to maximize the likelihood that all 14 days of dosing would occur
during the non-bleeding days of the menstrual cycle. Participants administered five of the 14
doses in the clinic with a study staff member in the room, but with a curtain drawn for privacy.
The other nine doses were to be self-administered at home at approximately the same time
each day. Both gels (Table 1) were manufactured and packaged in identical individually
wrapped, prefilled, single-use, metered dose applicators (HTI Plastics; Lincoln, NE) at the Population Council’s Good Manufacturing Practices facility (Center for Biomedical Research,
New York, NY). PC-6500 was manufactured using recombinant plant-produced GRFT [20].
The two study gels (PC-6500 and PC-535) differed imperceptibly in appearance; both were
translucent with a faint beige color.
A Population Council statistician not associated with the trial created the randomization
scheme that pre-assigned participants to either PC-6500 or placebo gel in a ratio of 7:3. Half of
the participants were assigned blood and cervicovaginal lavage (CVLs) sample collection at 4h
post dose; half were assigned to the 8h time point. Having different two time points for CVL
collection allowed us to explore the length of time product remains present and active in the
vagina. Randomization occurred in blocks of ten. Study staff received a list of kit numbers and
specimen time point randomization assignments for 20 participants. All investigators, study
staff and participants were blinded to product assignments. The post-dose specimen time
points (4h, 8h and 24h) were not blinded. Due to inclement weather, specimen collection for
one participant in the PC-6500 group was done at 6h instead of 8h post first dose.
Due to slower than anticipated accrual, it was not feasible to enroll all 20 women within the
time and budget available. Therefore, the protocol was amended so that starting with the tenth
enrollee, participants were assigned a kit number and time point, on a case-by-case basis, to
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Table 1. Composition of PC-6500 and PC-535 (placebo) gel.
Ingredients

Composition/Quantity (g)

Percent (%w/w)

Function

PC-6500
Griffithsin Solution (GRFT content 18.9 mg/mL)

108.98a

5.45b

API

WFI Quality Sterile Filtered Water

1812.78

90.64

Solvent

Sodium Acetate Trihydrate

5.24

0.26

Buffering agent

Sodium chloride

7.00

0.35

Osmolality adjuster
Gel base/ Vehicle

Carrageenan

62.00

3.10

Methylparaben

4.00

0.20

Preservative

1N Hydrochloric Acid

q.s.

q.s.

pH Adjuster

q.s

q.s.

pH Adjuster

1919.76

95.99

Solvent

Sodium Acetate Trihydrate

5.24

0.26

Buffering agent

Sodium chloride

7.00

0.35

Osmolality adjuster

1N Sodium Hydroxide

PC-535
WFI Quality Sterile Filtered Water

a
b

Carrageenan

64.00

3.20

Gel base/ Vehicle

Methylparaben

4.00

0.20

Preservative

1N Hydrochloric Acid

q.s.

q.s.

pH adjuster

1N Sodium Hydroxide

q.s

q.s.

pH adjuster

GRFT content = 2.06g.
GRFT weight % = 0.1%.

As needed, HCl and NaOH were used to bring the in-process pH into the 6.8 to 7.5 range.
https://doi.org/10.1371/journal.pone.0261775.t001

maximize the number of women assigned to product vs. placebo, and to maintain the balance
in post-dose specimen collection time points.

Outcome measures and analytical methods
The schedule of visits and procedures performed in the OL and randomized periods of the
study are presented in Tables 2 and 3, respectively. Outcome measures and analytical methods
are described in detail below. The schedule was designed to collect BL samples and 24h post
last gel samples (randomized phase) in late luteal phase to minimize effects of the menstrual
cycle on exploratory outcomes.

Clinical safety and exposure
Safety was evaluated at each study visit (Tables 2 and 3). Safety endpoints included treatment
emergent adverse events (TEAEs) and medical significance, in the investigator’s judgment, of
abnormalities in physical exams, pelvic exams, cervical and vaginal biopsies, and clinical laboratory parameters once product had been administered. AEs were coded using the Medical
Dictionary for Regulatory Activities (MedDRA, Version 21.0), and graded according to the
Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0 and the Female Genital Table [37] for Use in Microbicide Studies.
Safety data were summarized by treatment group (OL, randomized PC-6500, placebo).
Exposure was calculated by participant based on the number of applicators inserted vaginally,
as measured by dye stain assay (DSA) test (sensitivity 93%, specificity 100%) [38, 39].
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Table 2. Visits and assessments, open label period.
Visit/Study Day

Visit 1: Enrollment/Day 1

Visit 2: Day 2

Visit 3: Day 8

SINGLE DOSE IN CLINIC

24H POST-DOSE

CLOSING

Adverse events

Pre- and post-dose

24h post-dose

Final safety assessment

EKG

Pre-dose

24h post-dose

N/A

Vital signs

Pre- and post-dose

24h post-dose

Final safety assessment

Urinalysis

If indicated

If indicated

Final safety assessment

SAFETY/EXPOSURE

Physical exam

If indicated

If indicated

Final safety assessment

Pelvic exam

Pre-dose

If indicated

Final safety assessment

Clinical labs (hematology, chemistry, coagulation)

Pre- and post-dose

24h post-dose

Final safety assessment

Used applicator collected for DSA testing

Post-dose

N/A

N/A

Pre-dose and 0.5,1,2,3,4,6,8,10,12h post-dose

24h post-dose

N/A

Pre-dose

24h post-dose

N/A

PK
Plasma blood draw
EXPLORATORY
CVLs to measure API concentration and PD
N/A—not applicable.
API—active pharmaceutical ingredient.
CVLs—cervicovaginal lavage samples.
DSA—dye stain applicator.
EKG—electrocardiogram.
PD—pharmacodynamics.
PK- pharmacokinetics.
https://doi.org/10.1371/journal.pone.0261775.t002

Rapid Stain Identification (RSID) test
Swabs and CVLs were tested for presence of semenogelin using the RSID test (Independent
Forensics, Lombard, IL).

Histopathology
The histopathological assessment was performed by board-certified gynecologic pathologist
using inflammation scoring as detailed in S1 Table.

PK and concentrations of GRFT in CVLs
Concentrations of GRFT in plasma and in CVLs collected using 10 ml of sterile normal saline
were measured by a validated indirect sandwich ELISA. 96-well Immulon 2HB microplates
(Thermo Scientific, Rockford, IL) were pre-coated with HIV-1BaL gp-120 (NIH Reagent Program Cat#49610, Germantown, MD). After blocking, the samples were added to the plate in
duplicate. A goat anti-GRFT detection antibody (Pacific Immunology, Ramona, CA) was
added and the mixture, followed by a rabbit anti-goat-HRP secondary antibody (Southern Biotech, Birmingham, AL). Ultra-TMB substrate (Thermo Scientific) was added followed by sulfuric acid (Thermo Scientific). Plates were washed and read on the Emax microplate reader
(Molecular Devices, Sunnyvale, CA) at 450 nm (570 nm for reference) using the SoftMax Pro
GxP 5.4.6 software (Molecular Devices). The lower limits of quantification (LLOQs) were 10
ng/mL and 1.25 ng/mL for plasma and CVL, respectively.
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Table 3. Visits and assessments, randomized period.
Visit/Study Day

BASELINE Day 1
DOSE 1

Day 3

Day 8

Day 11

Day 14

DOSE 3

DOSE 8

DOSE 11

DOSE 14

Day 15

Day 21

Day 28

FINAL
SAFETY

Adverse events

Yes

Pre-/post-dose

Pre-/post-dose Pre-/post-dose Pre-/post-dose

Pre-/post-dose

Yes

Yes

Yes

Vital signs

Yes

Pre-/post-dose

Pre-/post-dose Pre-/post-dose Pre-/post-dose

Pre-/post-dose

Post-dose

Yes

Yes

If indicated

If indicated

If indicated

If indicated

If indicated

If indicated

If indicated

Yes

If
indicated

Yes

Pre-dose

If indicated

Pre-dose

Pre-dose

If indicated

If indicated

Yes

N/A

If indicated

If indicated

If indicated

If indicated

If indicated

If indicated

If indicated

Yes

If
indicated

Yes

N/A

N/A

N/A

N/A

N/A

Yes

N/A

N/A

Clinical labs

If indicated

Pre-dose

Pre-dose

Pre-dose

Pre-dose

Pre-dose

N/A

Yes

If
indicated

DSA testing

N/A

Post-dose

Post-dose

Post-dose

Post-dose

Post-dose

N/A

N/A

N/A

ADA (serum)

N/A

Yes

N/A

N/A

N/A

Yes

N/A

Yes

Physical exam
Pelvic exam
Urinalysis
Vaginal/cervical
biopsy

Yes

Plasma PK

N/A

Pre-dose; 4 or 8h
post-dose

Single PK

Single PK

Single PK

Pre-dose;
0.5,1,2,4,6,8h postdose

24h postdose 14

N/A

N/A

API, PD, immune
mediators (CVLs)

N/A

Pre-dose; 4 or 8h
post-dose

N/A

N/A

N/A

N/A

24h postdose 14

N/A

N/A

Cervical
transcriptome
(biopsy)

Yes

N/A

N/A

N/A

N/A

N/A

Yes

N/A

N/A

N/A—not applicable.
ADA- anti-drug antibodies.
API—active pharmaceutical ingredient.
CVLs—cervicovaginal lavage samples.
DSA—dye stain assay.
PD—pharmacodynamics.
PK- pharmacokinetics.
https://doi.org/10.1371/journal.pone.0261775.t003

Cytokine and chemokine (CC/CK) concentrations in CVL supernatants
before and after gel use
Interleukin (IL)-1β (lower limit of detection (LLD) 0.3pg/mL), IL1 RA (LLD 13.1 pg/mL), IL-6
(LLD 0.5 pg/mL), CCL5 (LLD 0.19 pg/mL), CXCL8 (LLD 0.4 pg/mL), CCL20 (LLD 70.4 pg/
mL) were measured using an electrochemiluminescence (ECL) platform (Meso Scale Discovery (MSD), Gaithersburg, MD) [40]. Each ECL immunoassay was optimized to allow detection
of each biomarker within the linearity concentration range in the clarified CVL samples.
IL1RA was tested in duplicates at 50- and 100-fold dilutions and when values exceeded the precision range of the assay, at an additional 1000-fold dilution. Other mediators were tested at a
2-fold or a 4-fold dilution, and where applicable undiluted, to generate duplicate values within
linearity. The serial dilution of CVL samples resulted in reproducible values within the linearity range of each assay proving by accepted immunoassay methodology [41, 42] no matrix
interference due to potential presence of study gel or other CVL matrix components. In addition, to rule out interference with the presence of gels, serial dilutions of a CG-containing gel
were prepared in saline and mixed with equal volumes of biomarker solutions of known concentrations. Full CC/CK recovery was achieved in the concentration range of CG detected in
CVL [43].
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RNA sequencing
Total RNA was isolated from ectocervical biopsy tissues taken from participants in the randomized study at BL pre-dose and post-dose 14 (one biopsy at each time point) and frozen in
RNAlater (Ambion) following the manufacturer’s instructions (RNeasy Fibrous Tissue Mini
Kit (Qiagen; Germantown, MD)). The quality and purity of the extracted RNA were measured
by the Agilent Bioanalyzer (Agilent, Santa Clara, CA). RNA was labeled, sequenced at the
Rockefeller University (RU) Genomics Center by using Illumina TruSeq technology (75bp,
>30M coverage) and analyzed as we previously published [44]. A multidimensional scaling
plot (MDS) plot showing expression of top 500 genes in two dimensions was prepared within
edgeR (doi: 10.1093/bioinformatics/btp616). To visualize gene expression patterns before and
after gel treatment, a heatmap was plotted on the log transformation of count per million
(logCPM) through R heatmap package (Kolde R, Package ’pheatmap’ for R. Version 1.0.8
(2015). Specifically, the top 500 variant genes (based on p adj. value) were selected to represent
the heatmap. The volcano plots of gene expression according to the fold change and false discovery rate (FDR) adjusted p values were prepared through in-house R code.

ADAs in serum
ELISA plates were coated with 20 μg/mL of GRFT. Following blocking and washes, serum
samples and NM479 standards were added to the plate. For the samples, collected human
serum was diluted 1:50. For the standard curve, 2X concentrated NM479 (1000 ng/mL– 0.98
ng/mL) was diluted 1:1 in 25X diluted serum (Innovative Research), for a final serum dilution
of 50X and final NM479 concentrations ranging from 500 ng/mL to 0.49 ng/mL. Then biotinylated KQ-GRFT was added to the plates. KQ-GRFT is a modified version of Q-GRFT that contains a lysine at the N-terminus of the protein. Then plates were washed followed by
incubation with horseradish peroxidase conjugated with streptavidin (SA-HRP) (Pierce).
ADAs were detected using TMB (SeraCare), and the reaction was stopped with addition of sulfuric acid. OD 450 nm was measured on a Biotek Synergy HT plate reader.

Anti-HIV-1ADA-M activity of CVLs in TZM-bl MAGI assay
The multinuclear activation of a galactosidase indicator (MAGI) assay in TZM-bl cells
(NIH AIDS Reagent Program) [45] was modified for evaluation of activity of GRFT in CVLs.
Briefly, TMZ-bl cells cultured in 96-well white-opaque flat bottom microplates (Thermo Scientific) received different dilutions of non-clarified CVLs. GRFT solutions (between 100 and
0.015 ng/mL) prepared by diluting CMB-BDS-0900-003 GRFT stock (17 mg/mL) with cell culture medium were used as a control in the antiviral assay. All wells (including virus controls
but excluding cell controls) were immediately challenged with 100–200 HIV-1ADA-M infectious particles and stained using the MAGI assay following incubation [45]. All CVL dilutions
and controls were tested in triplicate.

Anti-HPV activity in CVLs
The anti-HPV activity of selected CVL samples was tested in HeLa cells using the luciferase
assay [46, 47]. Briefly, HeLa cells cultured overnight at 105 cells/mL in 96-well clear flat bottom
microplates (Thermo Scientific) were incubated with different dilutions of non-clarified CVLs
in triplicate. A 3% carrageenan gel (Population Council, lot#160613B6500 placebo TZ) diluted
to between 1000 and 0.15 ng/mL with cell culture medium was used as a control in the antiviral assay. All wells (including virus controls but excluding cell controls) were immediately
challenged with HPV16 PsV (5x105 copies per well) and stained using the Pierce Firefly
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Luciferase Glow Assay (Thermo Scientific) [46] following incubation. All CVL dilutions and
controls were tested in triplicate.

Anti-HIV-1BaL activity in CVLs in ectocervical explants
Ectocervical explants (5x5mm) were prepared as we previously described [48], stimulated with
PHA (5 μg/mL) and IL-2 (100 U/mL) and then challenged with 500 TCID50 HIV-1BaL/explant
(in duplicate) in the presence of non-clarified CVLs. HIV-1BaL was generated and titered as
previously described [43]. Ten μL of viral stock diluted in CVL (500 TCID50 of HIVBaL; 1.79μl
of virus and 8.21μl of CVL) was applied on the top of the epithelium for 2h at 37˚C in 5% CO2
followed by a wash out. Tissues were then cultured in complete DMEM for 14 days (d). Where
feasible, untreated control (culture medium) was included. Also, to discriminate between the
viral inoculum and de novo viral replication lamivudine (3TC: 4μL of 500μM stock applied on
the epithelium) control was included. Tissue culture supernatants were collected right after
washes (d0) and during culture (d3, 7, 11, 14). Infection was monitored with validated HIV
gag reverse transcription-quantitative PCR (qRT-PCR) with LLOQ 20,000 copies/mL. Any
p
value below LLOQ was set to 200001/ 2 = 1099.74. Endpoint “soft” (SOFT; maximal viral
growth) and cumulative (CUM) (d3 to 14) analyses were performed [43, 49].

Epithelial integrity and ectocervical tissue viability in vitro
We explored if exposure to PC-6500 induces tissue toxicity, which may interfere with testing
of anti-HIVBaL activity of CVLs. Effects of PC-6500 on epithelial integrity and ectocervical tissue viability were analyzed by Hematoxylin and Eosin (H&E) staining and the MTT assay [3(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide] assay [50], respectively.
Human ectocervical tissues without gross pathological changes were obtained from routine
hysterectomies through the National Disease Research Interchange (NDRI; Philadelphia, P)
and transported overnight (ON) in RPMI medium. 5x5mm and 3x3mm explants were prepared as we previously described for macaque and human cervicovaginal tissues [48, 50].
Undiluted gels, PC-6500 (batches 131004B6500TR and 141027A6500TZ) and PC-535 (batch
130918A525TR), were applied on the epithelial surface of 5x5m explants and left ON (polarized cultures). Alternatively, 3x3mm explants were immersed in 1:30 and 1:100 diluted gels
ON. Following incubation, tissues were processed for H&E staining (polarized cultures) or the
MTT assay (immersion cultures).

Statistical analysis
As is typical for first-in-human studies, no formal sample size calculation was carried out for
this study. A sample size of seven participants in the single dose OL portion of the study, and
20 participants in the randomized portion (14 active; 6 placebo) was deemed sufficient to evaluate the safety of PC-6500 and to assess the PK of GRFT. Number and percent of participants
with TEAEs are summarized by treatment arm and relationship and toxicity. Descriptive statistics are presented by treatment arm for demographic and baseline characteristics and for
clinical endpoints. Analysis was done with SAS Version 9.4.
Log-normal generalized linear mixed models were used to analyze changes in CC/CK concentrations in CVL adjusting for treatment type. Treatment (PC-6500 or placebo) was a fixed
effect in the model and a random effect for each participant was included. Values below LLD
were assumed LLD/10. Pairwise differences were calculated using Tukey-adjusted 95% confidence intervals (CIs).
For transcriptome analysis, edgeR� v 3.16.5 [51] was used to normalize the samples and
Voom from limma# v 3.30.11 was applied to estimate the differential log fold change in the

PLOS ONE | https://doi.org/10.1371/journal.pone.0261775 January 20, 2022

9 / 24

PLOS ONE

Phase 1 trial of griffithsin formulated in a carrageenan vaginal gel

expression of genes. An FDR adjusted p value <0.05 was used to determine if there was a
change in cervical gene expression post gel application.
For analysis of anti-HIV-1ADA-M activity of CVLs in TZM-bl MAGI assay, the EC50 and
95% CIs were calculated using a curve-fitting analysis (GraphPad Prism 5.0 Software, Inc., La
Jolla, CA). GRFT concentrations and anti-HIV activity in CVLs were correlated using the
Spearman correlation analysis (GraphPad Prism). Similarly, for analysis of anti-HPV activity
in CVLs, the EC50 and 95% CIs were calculated using a curve-fitting analysis (GraphPad
Prism).
For analysis of anti-HIV-1BaL activity of CVLs in ectocervical explants, log-normal generalized linear mixed models were used. The models examined the relationship between SOFT
and CUM as the independent variables and treatment type, CVL collection time and their
interaction as the dependent variables (fixed effects). A random intercept for each participant
was included. Pairwise comparisons were calculated and stepdown simulation-adjusted 95%
CIs reported. GRFT concentrations and anti-HIV activity in CVLs were correlated using the
Spearman correlation analysis (GraphPad Prism).
For analysis of tissue viability after exposure to gels in vitro, log-normal generalized linear
mixed models with random intercepts were used. Optical density (OD) 570/tissue weight (g)
was the response variable. Predictors were gel treatments. Tissue donor was included as a random effect (SAS).

Results
Disposition and demographics
Seven participants were enrolled in the single dose OL period, all of whom completed the
study (October-November 2017). As summarized in CONSORT Fig 1, 24 women were
screened for the randomized portion of the study and 15 participants enrolled: 12 in the PC6500 group and 3 in the placebo group. Thirteen participants (10/12 PC-6500; 3/3 placebo)
completed the study (March-August 2018). Of the nine women who did not enroll, one chose
to withdraw after starting the screening process and the other eight were ineligible due to
underlying conditions (n = 6), including anemia, irregular bleeding, and trichomonas; inability to tolerate the pelvic exam (n = 1) and the investigator’s discretion (n = 2). Data collection
ended based on the timeframe and resources available from the donor. Two participants in the
PC-6500 arm withdrew prior to dosing, one due to a trichomonas infection detected at enrollment, and the other for personal reasons.
Participants in both periods of the study were approximately 32 years of age, on average,
representing a mix of races, ethnicities and other background characteristics (see Table 4).

Exposure
Fig 2 illustrates the study design, including in-clinic and at-home dosing. All 7 participants in
the OL period received one PC-6500 dose administered by the study clinician. The median
dose exposure was 13 (range 3–14) in the randomized PC-6500 group and 14 (range 8–14) in
the placebo group. Two of the three participants in the placebo group inserted all 14 doses per
dye stain applicator (DSA) testing [38, 39]. In the randomized PC-6500 group, five of the ten
participants inserted all 14 doses per DSA testing. Of the five participants in the randomized
PC-6500 group who did not insert all applicators per the DSA, two inserted 13/14 doses, one
inserted 12/14 doses, one inserted 8/14 doses and one appeared to have inserted only 1 out of
14 doses, including 4 of the 5 doses self-inserted in the clinic.
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Fig 1. CONSORT flow diagram.
https://doi.org/10.1371/journal.pone.0261775.g001

Clinical safety
A total of 34 treatment emergent adverse events (TEAEs) were reported (Table 5) in five out of
seven participants in the OL period and in 11 out of 13 participants (8 PC-6500, 3 placebo) in
the randomized period. Only one event (vaginal discharge reported by a woman in the randomized PC-6500 group) was considered possibly related to study drug. The event was moderate in severity and resolved spontaneously without any intervention.
Most adverse events (AEs) were transient and mild. Three TEAEs were judged to be of
moderate severity: hyperkalemia, thrombocytopenia and hypophosphatemia, none of which
were related to study drug or required additional interventions; these TEAEs occurred in 2
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Table 4. Participant demographics (n = 20).
Open Label PC-6500

Randomized PC-6500

Randomized Placebo

Overall

(n = 7)

(n = 10)

(n = 3)

(n = 20)

Age (Years)
Mean (SD)

31.9 (7.90)

31.9 (5.67)

33.3 (10.41)

Range

25–43

24–40

25–45

32.1 (6.83)
24–45

n

(%)

n

(%)

n

(%)

n

(%)

Hispanic or Latina

1

14.3%

2

20.0%

0

0.0%

3

15.0%

Not Hispanic or Latina

6

85.7%

8

80.0%

3

10%

17

85.0%

Ethnicity

Race a
Black or African American

2

28.6%

4

40.0%

2

66.7%

8

40.0%

White

4

57.1%

7

70.0%

1

33.3%

12

60.0%

Asian

0

0.0%

1

10.0%

0

0.0%

1

5.0%

Other

1

14.3%

0

0.0%

0

0.0%

1

5.0%

Married/Cohabiting

4

57.1%

5

50.0%

1

33.3%

10

50.0%

Single

2

28.6%

5

50.0%

2

66.7%

9

45.0%

Divorced

1

14.3%

0

0.0%

0

0.0%

1

5.0%

College Graduate

5

71.4%

8

80.0%

2

66.7%

15

75.0%

Some College

2

28.6%

2

20.0%

1

33.3%

5

25.0%

Marital Status

Level of Education

a

Participants could select more than one race; total may be greater than 100%.

https://doi.org/10.1371/journal.pone.0261775.t004

participants in the PC-6500 arm. TEAEs that required additional interventions were seasonal
allergies (medication), and musculoskeletal pain (medication).
No serious AEs occurred. There were no clinically significant abnormalities found in physical or pelvic exams, and no clinically relevant shifts in any laboratory parameters.

Histopathology
Ectocervical and vaginal biopsies were collected from 15 participants. All 15 participants had
baseline (BL) biopsies and 13 had biopsies collected both at BL and one day after last gel application (10 PC-6500, 3 placebo) (n = 1 ectocervical and n = 1 vaginal). Evaluation of histologic
data disclosed no findings of dysplasia or hyperplasia at BL or post gel administration. Most of
the biopsies had mild to moderate inflammation (grades 1–2) in the epithelium/stroma at BL
and post PC-6500 and placebo gel administration (S1 Table). In paired BL and post gel samples
within PC-6500 group, the semiquantitative scores in cervical epithelium and stroma ranged
from 0 to 2.5+ at BL and from 0 to 2 post gel. In vaginal epithelium and stroma the scores ranged from 0 to 1+ at BL and from 0 to 2 post gel. In placebo group, the scores in cervical epithelium and stroma ranged from 0 to 1 at BL and from 0.5 to 1+ post gel. In vaginal epithelium
and stroma the scores ranged from 0 to 2 at BL and from 0 to 2+ post gel. No worsening of
inflammation post gel administration was evident (S1 Table).

GRFT PK in plasma
A total of 77 plasma samples from the OL period were collected, of which 23 were unevaluable
due to coagulation resulting in a non-specific background. A total of 54 (71%) samples were
analyzed. All samples from the randomized period were analyzed. GRFT levels in all samples
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Fig 2. Clinical trial design.
https://doi.org/10.1371/journal.pone.0261775.g002

Table 5. Adverse event summary.
Open Label PC-6500 (n = 7)

Randomized PC-6500 (n = 10)

Randomized Placebo (n = 3)

Overall (n = 20)

5 (71.4%)

8 (80%)

3 (100%)

16 (80%)

With 1 TEAE

3 (42.9%)

3 (30%)

1 (33.3%)

7 (35%)

With 2 TEAEs

2 (28.6%)

1 (10%)

1 (33.3%)

4 (20%)

0 (0%)

4 (50%)

1 (33.3%)

5 (25%)

7

21

6

34

Number of participants with any TEAE, n (%)

With 3 or more TEAEs
Number of events
Relationship, n (%)
Not Related

7 (100.0%)

14 (66.7%)

4 (66.7%)

25 (73.5%)

Unlikely

-

6 (28.6%)

2 (33.3%)

8 (23.5%)

Possible

-

1 (4.8%)

-

1 (2.9%)

Grade 1

7 (100.0%)

17 (81.0%)

6 (100%)

30 (88.2%)

Grade 2

-

3 (14.3%)

-

3 (8.8%)

Grade 3

-

1 (4.8%) a

-

1 (2.9%)

-

1 (4.8%)

-

1 (2.9%)

Toxicity grade, n (%)

b

Vaginal discharge
a

AE with Grade 3 was for Activated partial thromboplastin time prolonged and marked as Grade 3 per DAIDS guidelines. The lab result was a probable lab error as the

repeat test was within normal limits.
b

Possibly related to the study product.
TEAE—treatment emergent adverse events.

https://doi.org/10.1371/journal.pone.0261775.t005
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Fig 3. GRFT concentrations in CVL from participants in the randomized phase. GRFT concentrations 4h (or 6h) or 8h after single gel application
and 24h after last gel application. 0h represents pre-gel dose BL. Each symbol represents an individual subject. Data below LLOQ are shown as 0. BL
and 4h CVL samples from one subject in PC-6500 group were suspected to be switched at the time of collection. This has been adjusted for the
presentation. Non-specific background was detected in 4h and 24h time points CVLs from a single subject in placebo group. These data were excluded.
https://doi.org/10.1371/journal.pone.0261775.g003

were below LLOQ (10 ng/mL). As GRFT was undetectable after a single dose, or after multiple
doses, no PK parameters were calculated.

GRFT concentrations in CVLs
Among participants randomized to PC-6500, CVLs collected at BL, 4h (or 6h) and 8h after single gel administration and 24h after dose 14 were evaluated. GRFT concentrations post gel
administration ranged from between 0.0 and 82.1 μg/mL (Fig 3).

CC/CK concentrations in CVLs
Biomarkers of inflammation were chosen for their established role in vaginal inflammation
and HIV risk, reliable detection in cervicovaginal secretions, and clinically validated acceptance for microbicide safety evaluation [41, 52, 53]. CC/CK were measured in CVLs collected
at BL and 24h post last gel administration in the randomized study (Fig 4). Concentrations of
IL1β (least square mean ratio for post PC-6500 dosing: BL = 0.800, 95% CI [0.342,1.870],
IL1RA (ratio = 0.364, 95% CI [0.119, 1.111]) and IL6 (ratio = 0.496, 95% CI [0.161, 1.529])
after repeated PC-6500 gel application were similar to BL. Decreased concentrations of
CXCL8 after administration of both PC-6500 and placebo gels (ratio = 0.199, 95% CI [0.104,
0.380]; 0.032 [0.002, 0.466], respectively); decreased concentrations of CCL5 after administration of PC-6500 (ratio = 0.191, 95% CI [0.051, 0.720]) and decreased concentrations of CCL20
after administration of PC-6500 (ratio = 0.112, 95% CI [0.023, 0.546]) were detected. As RSID
testing of CVLs and swabs did not detect semen in any samples, interference of immune mediators present in semen with the results was ruled out.

Cervical tissue transcriptome
Gene expression was analyzed in ectocervical biopsies collected at BL and 24h post last gel
administration in the randomized period. An MDS plot revealed that most of the analyzed
samples clustered together (Fig 5A), suggesting similar tissue gene expression before and after
gel exposure. No specific patterns of gene expression before or after gel exposure were evident
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Fig 4. Concentrations of mediators of inflammation in CVLs. CVLs from participants in the randomized study (n = 10 PC-6500, n = 3 placebo) were
collected pre-dose at BL and 24h post last gel application (D15) using saline. One subject (PC-6500 group) was excluded from the analysis as BL and 4h
time-point CVLs were suspected to be switched at the time of collection. CVL samples with suspected blood (one post placebo gel, one post PC-6500
and one BL sample in PC-6500 group) were excluded from the analysis. Dotted lines represent lower limit of detection (LLD).
https://doi.org/10.1371/journal.pone.0261775.g004

on the heatmap presentation (Fig 5B). Gene expression after repeated gel administration was
similar to BL, as shown on the volcano plots (Fig 5C and 5D).

ADAs
ADAs were evaluated in the randomized period of the study. No ADAs were detected at
the tested time points (BL; d14, d21 and d28 post first gel application). Only one participant
had a low positive optical density (OD) value of approximately 0.1 at BL. However, because
we did not observe any increase in the later time points, we attributed the positive signal at
BL to be an artifact or a pre-existing immune response to something that cross-reacts with
GRFT.

Pharmacodynamics
Anti-HIV-1ADA-M and anti-HPV16 PsV activities in CVLs. The antiviral activity of
CVLs was tested in well-established TZM-bl and luciferase assays, as we previously published
[45, 46]. EC50 values in the TZM-bl assay (0.7 ng/mL ± 0.6) based on GRFT concentrations
suggest that CVL components did not affect the antiviral properties of GRFT. We were unable
to estimate EC50 values in two CVLs where GRFT was quantified due to a sub-optimal curve
fitting analysis (R square <0.8 and 95% CIs higher than 1log). As shown in Fig 6A, samples
with high GRFT concentrations resulted in lower EC50 values based on CVL dilution; the
more GRFT in the sample, the more dilution required to reach the EC50 value. Anti-HPV
activity was evaluated in all CVLs from participants in the placebo and PC-6500 groups. CVLs
recovered 4, 8 or 24h after gel application had EC50 values between 0.066 and 0.000032 (based
on sample dilution). The mean EC50 values, based on CVL dilution factor, with the 95% CIs,
were 0.071 [0.045; 0.097], 0.00026 [0.00004; 0.00055], 0.00042 [0.00013; 0.00069], 0.0074
[0.0034; 0.018] for CVLs collected at BL, 4, 8 and 24 hours after gel application, respectively.
EC50 values from CVLs collected at all three time points post gel application were lower than
BL EC50 values (Fig 6B). Lack of anti-HPV activity in CVL samples was noted for one participant in PC-6500 gel group, who appeared to have inserted only 1 of 14 doses according to the
DSA.
Anti-HIV-1BaL activity of CVLs in human ectocervical explants. Our previously published methodology for testing CVL activity in explants using an immersion tissue culture
model [43] was adapted for use with polarized tissue cultures. PHA/IL2 activated explants
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Fig 5. Ectocervical tissue transcriptome before and after repeated PC-6500 or placebo gel administration. Ectocervical gene expression in biopsies
collected at BL and 24h after 14 days repeated gel administration is shown as (A) MDS plot, (B) heatmap and (C, D) volcano plots. MDS plot was
prepared through plot MDS function within edgeR (doi: 10.1093/bioinformatics/btp616). The heatmap was constructed by edgeR using top 500 genes
based on LogCPM. Induction (red) and inhibition (blue) of expression (z-scores) are shown. The volcano plots of gene expression at BL and post gel
administration according to the fold change and adjusted p values (q < 0.05) were prepared through in-house R code. The y-axis corresponds to the
mean expression value of log10 (FDR; q), and the x-axis displays the log2 fold change (FC) value. Samples from 9 subjects in PC-6500 group and from
n = 3 subjects in placebo group were analyzed. Due to poor RNA quality, sample from one subject in PC-6500 group was excluded from the analysis.
https://doi.org/10.1371/journal.pone.0261775.g005

were challenged with HIV-1BaL in the presence of CVLs. Viral growth kinetics in individual
experiments are shown in S1 Fig. SOFT and CUM analyses demonstrated a decrease in
tissue HIV-1BaL infection after exposure to CVLs collected 4 and 6h post PC-6500 gel application compared to placebo gel vs. 0h CVL (SOFT ratio = -4.27, 95% CI [-7.34, -1.20]; CUM
ratio = -4.06, 95% CI [-6.96, -1.17]) (Fig 6C). No decrease in infection was observed after exposure to CVLs collected 8h post PC-6500 gel application compared to placebo gel vs. 0h (SOFT
ratio = -1.10, 95% CI [-5.00, 2.80]; CUM ratio = -1.05, 95% CI [-4.73, 2.63]) or at 24h vs. 0h
(SOFT ratio = -0.98, 95% CI [-3.64, 1.68]; CUM ratio = -1.01, 95% CI [-3.52, 1.50]) (Fig 6C).
GRFT concentrations in CVLs directly correlated with HIV-1BaL inhibition (Fig 6C). To rule
out potential contribution of toxicity in these experiments, epithelial integrity and tissue viability post gel application were evaluated in vitro. No changes in epithelial integrity (e.g., epithelial fractures) or decreased viability were observed (S2A and S2B Fig).
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Fig 6. CVL activity against HIV-1 and HPV16 PsV. (A) TMZ-bl cells were incubated with cell-free HIV-1ADA-M and different
dilutions of CVLs collected at BL, 4 or 8h post single GRFT/CG gel administration and 24h after 14 day repeated gel administration
(randomized study). The EC50 and 95% CI were calculated using a curve-fitting analysis with GraphPad Prism. The Spearman
correlation analysis demonstrated that the higher the concentration of GRFT in CVL, the more potent the antiviral activity against
HIV-1ADA-M in the MAGI assay. (B) HeLa cells were incubated with HPV16 PsV and different dilutions of CVLs collected at BL, 4 or
8h post single PC-6500 gel administration and 24h post last gel administration (randomized study). The EC50 and 95% CI were
calculated using a curve-fitting analysis with GraphPad Prism. (C) Polarized cervical explant cultures were challenged with 500 TCID50
HIV-1BaL in the presence of CVLs collected at BL; 4, 6 or 8h post single and 24h after 14 day repeated gel administration (randomized
study) applied on the epithelial surface for 2h (two explants per condition). Tissues were washed and cultured for 14d. Infection was
monitored by HIV gag qRT-PCR using supernatants collected every 3-4d. 3TC (4μl of 500μM stock applied on the epithelium) control
was included where feasible. The Spearman correlation analysis demonstrated that the higher the concentration of GRFT in CVLs, the
more potent the antiviral activity against HIV-1BaL.
https://doi.org/10.1371/journal.pone.0261775.g006
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Discussion
In this first-in-human trial of 0.1% GRFT in a CG gel (PC-6500) there was no measurable systemic absorption, and no safety signals were detected in healthy, HIV-negative women using
the gel for up to 14 consecutive daily doses. PC-6500 remained active against HIV and HPV in
the presence of vaginal fluids in vitro. These results concur with preclinical assessments of
GRFT and the GRFT/CG combination by the Population Council and others, demonstrating
lack of systemic absorption, safety and activity against HIV and other STIs (HPV and HSV)
[33, 34, 54].
No significant histopathological changes in cervical and vaginal mucosa and no ADA were
detected. Consistent with this data, toxicology studies in small animal models following
repeated vaginal administration of a GRFT/CG gel or intravenous (IV) administration of
GRFT demonstrated no adverse events and showed that GRFT/CG gel is non-irritating. IV
administration of GRFT in rats resulted in no detectable anti-drug antibodies (ADAs) [54].
Furthermore, rather than an increase in inflammatory CC/CK post gel application, a
decrease in concentrations of CXCL8, CCL5 and CCL20 was detected post PC-6500 administration. Notably, CXCL8 and CCL20 are induced early during vaginal SIV infection in
macaques followed by secondary inflammatory process likely driven by CCL5 and other CKproducing cells, leading to recruitment of immune cells and fueling infection [55]. Increased
gene expression of CXCL8 and CCL20 in the cervix following exposure to Nonoxynol-9 (N9)
gel is considered to be a “harm signal” [56]. CCL5 is involved in both the blocking of HIV
binding to CCR5 on target cells and the recruitment of these target cells to the female genital
tract [57–59]. The decreased concentrations of CXCL8, CCL5 and CCL20 post gel administration suggest a possible anti-inflammatory effect of PC-6500 gel.
Analysis of changes in gene expression may provide additional safety information in PrEP
trials. PC-6500 or placebo gel did not induce changes in the ectocervical tissue transcriptome.
CVLs from women who used PC-6500 showed potent anti-HIV activity in cell-based and
explant assays. In the polarized cervical explant model, which allows application of CVL and
HIV on the epithelial surface mimicking the in vivo scenario, infection inhibition was detected
after exposure to CVLs collected 4h or 6h post gel administration, but not 8h post gel. These
data are consistent with in vivo data demonstrating significant protection of GRFT/CG FDI
against vaginal simian human immunodeficiency virus (SHIV SF162P3) challenge [54].
DMPA-treated macaques were challenged with high dose vaginal SHIV SF162P3 4h after vaginal administration of either GRFT/CG FDIs (2 of 10 infected) or control CG FDIs containing
all the same components except GRFT (10 of 10 infected). The activity of GRFT against SHIV
SF162P3 infection in mucosal targets (in explants) was predictive of in vivo efficacy [54].
GRFT/CG FDIs were also effective against HSV-2 in mice [54]. Consistent with our published
data on anti-HPV activity of CG and GRFT [34, 54], CVLs from participants in the PC-6500
and placebo groups inhibited HPV in vitro.
The study had several limitations. Although no sample size calculation was carried out,
which is typical for first-in-human studies, the small sample size resulted in imbalance in baseline characteristics and may have been underpowered to detect some PD effects and may have
limited the safety, PK and PD assessments. The potential limitations of the small sample size
were compounded by imperfect adherence in half of the women in the PC-6500 group, which
may have further limited the chances of detecting safety signals. In particular, the DSA results
that indicated one participant inserted only a single dose of PC-6500 highlights the importance
of emphasizing and assessing adherence even in early-stage clinical trials [60]. The study was
not designed to assess intra-person heterogeneity or to formally monitor ADA response,
which involves testing of samples over an extended period of time. Measurement of
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cervicovaginal fluid dilution in CVL was not feasible. Variation in the cervicovaginal fluid volume could have contributed to the variation in detected GRFT concentrations, CC/CK concentrations and could have affected PD results. Although we did not detect CG-mediated antiHIV activity in CVLs derived from subjects administered placebo gel, we cannot exclude contribution of CG to the observed infection inhibition [43, 61]. Given modest anti-HPV activity
of GRFT, it is likely that observed anti-HPV activity in the CVLs was mediated by CG [34].
In conclusion, PC-6500 represents a promising on-demand MPT product. PC-6500 containing potent non-ARV lectin GRFT may be preferred for individuals at high risk of HIV
acquisition and who do not know their HIV status, decreasing the risk of developing drug
resistance. Due to the anti-HPV and anti-HSV-2 activity of GRFT and CG, PC-6500 may also
decrease HPV infection and HSV-2 infection/shedding, bolstering the anti-HIV activity of this
prevention product. Lack of significant adverse events in clinical, laboratory or histopathological evaluations points to the safety of this MPT product.
Overall, a GRFT-containing on-demand or sustained-release product would fill an important gap in the current ARV-dominated prevention product pipeline. Data from this trial support the further clinical testing of GRFT/CG formulations for informing doses of GRFT for
future trials and other GRFT delivery systems.

Supporting information
S1 Fig. HIV-1BaL infection kinetics in ectocervical tissues. PHA/IL-2 activated polarized
ectocervical explants were challenged with HIV-1BaL in the presence of CVLs collected at (A)
BL (0h CVL), 4h post first gel dose (4h CVL) and 24h post last dose (24h CVL); (B) 0h, 6h post
first gel dose (6h CVL) and 24h post last dose; (C) 0h, 8h post first gel dose (8h CVL) and 24h
post last dose. Controls included tissues challenged in the presence of medium (Control) or
3TC (diluted in medium). All CVLs collected from an individual subject were tested using
ectocervical tissues from a single tissue donor. Each graph represents results using CVLs from
an individual subject. Shown are MEAN±SEM HIV gag copies/mL of two explants per condition. One subject in placebo group had single explants included in control and 3TC conditions. BL and 4h CVL samples from one subject in PC-6500 group were suspected to be
switched at the time of collection. This has been adjusted for the presentation and statistical
analysis.
(TIF)
S2 Fig. PC-6500 is not toxic to human ectocervical mucosa. (A) Polarized human ectocervical explants were cultured for ~18h in the presence of neat gels vs. medium applied on the epithelium (single explant/condition). To assess epithelial integrity after exposure to the gels,
tissues were washed, paraffin-embedded, and stained with H&E. Representative of at least 3
experiments is shown. (B) Alternatively, tissues were immersed in medium containing diluted
PC-6500 (vs. medium, diluted placebo and Gynol controls) (n = 2–3 explants/condition). Tissue viability was determined using MTT assay (OD570 of the formazan product was normalized to the dry weight of the explants). Each symbol indicates an individual donor and the
Mean±SEM of the Log10 OD570/g of tissue for each condition is shown.
(TIF)
S1 File.
(PDF)
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Barbara A. Friedland, George W. Creasy, Marlena G. Plagianos, Thomas M. Zydowsky.

References
1.

http://www.unaids.org/en/resources/fact-sheet

2.

Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363(27):2587–99. https://
doi.org/10.1056/NEJMoa1011205 PMID: 21091279

PLOS ONE | https://doi.org/10.1371/journal.pone.0261775 January 20, 2022

20 / 24

PLOS ONE

Phase 1 trial of griffithsin formulated in a carrageenan vaginal gel

3.

Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for
HIV prevention in heterosexual men and women. N Engl J Med. 2012; 367(5):399–410. https://doi.org/
10.1056/NEJMoa1108524 PMID: 22784037

4.

Anderson PL, Glidden DV, Liu A, Buchbinder S, Lama JR, Guanira JV, et al. Emtricitabine-tenofovir
concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med.
2012; 4(151):151ra25. https://doi.org/10.1126/scitranslmed.3004006 PMID: 22972843

5.

Molina JM, Charreau I, Spire B, Cotte L, Chas J, Capitant C, et al. Efficacy, safety, and effect on sexual
behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. Lancet HIV. 2017; 4(9):e402–e10. https://doi.org/10.1016/S2352-3018(17)30089-9
PMID: 28747274

6.

Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for
HIV infection among African women. N Engl J Med. 2012; 367(5):411–22. https://doi.org/10.1056/
NEJMoa1202614 PMID: 22784040

7.

Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015; 372(6):509–18. https://
doi.org/10.1056/NEJMoa1402269 PMID: 25651245

8.

https://www.hptn.org/news-and-events/press-releases/hptn-083-study-demonstrates-superioritycabotegravir-prevention-hiv

9.

https://www.hptn.org/news-and-events/press-releases/hptn-084-study-demonstrates-superiority-ofcab-la-to-oral-tdfftc-for

10.

Kwakwa HA, Bessias S, Sturgis D, Mvula N, Wahome R, Coyle C, et al. Attitudes Toward HIV PreExposure Prophylaxis in a United States Urban Clinic Population. AIDS Behav. 2016; 20(7):1443–50.
https://doi.org/10.1007/s10461-016-1407-9 PMID: 27115399

11.

Luecke EH, Cheng H, Woeber K, Nakyanzi T, Mudekunye-Mahaka IC, van der Straten A, et al. Stated
product formulation preferences for HIV pre-exposure prophylaxis among women in the VOICE-D
(MTN-003D) study. J Int AIDS Soc. 2016; 19(1):20875. https://doi.org/10.7448/IAS.19.1.20875 PMID:
27247202

12.

Corneli A, Perry B, McKenna K, Agot K, Ahmed K, Taylor J, et al. Participants’ Explanations for Nonadherence in the FEM-PrEP Clinical Trial. J Acquir Immune Defic Syndr. 2016; 71(4):452–61. https://doi.
org/10.1097/QAI.0000000000000880 PMID: 26536315

13.

Hendrix CW. HIV Antiretroviral Pre-Exposure Prophylaxis: Development Challenges and Pipeline
Promise. Clin Pharmacol Ther. 2018; 104(6):1082–97. https://doi.org/10.1002/cpt.1227 PMID:
30199098

14.

Ross J, Stover J. Use of modern contraception increases when more methods become available: analysis of evidence from 1982–2009. Glob Health Sci Pract. 2013; 1(2):203–12. https://doi.org/10.9745/
GHSP-D-13-00010 PMID: 25276533

15.

Cottrell ML, Yang KH, Prince HM, Sykes C, White N, Malone S, et al. A Translational Pharmacology
Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using
Tenofovir Disoproxil Fumarate With or Without Emtricitabine. J Infect Dis. 2016; 214(1):55–64. https://
doi.org/10.1093/infdis/jiw077 PMID: 26917574

16.

Passmore JA, Jaspan HB, Masson L. Genital inflammation, immune activation and risk of sexual HIV
acquisition. Curr Opin HIV AIDS. 2016; 11(2):156–62. https://doi.org/10.1097/COH.
0000000000000232 PMID: 26628324

17.

Emmanuel G, Folayan M, Undelikwe G, Ochonye B, Jayeoba T, Yusuf A, et al. Community perspectives on barriers and challenges to HIV pre-exposure prophylaxis access by men who have sex with
men and female sex workers access in Nigeria. BMC Public Health. 2020; 20(1):69. https://doi.org/10.
1186/s12889-020-8195-x PMID: 31941469

18.

Ortblad KF, Chanda MM, Musoke DK, Ngabirano T, Mwale M, Nakitende A, et al. Acceptability of HIV
self-testing to support pre-exposure prophylaxis among female sex workers in Uganda and Zambia:
results from two randomized controlled trials. BMC Infect Dis. 2018; 18(1):503. https://doi.org/10.1186/
s12879-018-3415-z PMID: 30286737

19.

Whitfield THF, John SA, Rendina HJ, Grov C, Parsons JT. Why I Quit Pre-Exposure Prophylaxis
(PrEP)? A Mixed-Method Study Exploring Reasons for PrEP Discontinuation and Potential Re-initiation
Among Gay and Bisexual Men. AIDS Behav. 2018; 22(11):3566–75. https://doi.org/10.1007/s10461018-2045-1 PMID: 29404756

20.

O’Keefe BR, Vojdani F, Buffa V, Shattock RJ, Montefiori DC, Bakke J, et al. Scaleable manufacture of
HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component. Proc Natl Acad Sci U S A. 2009; 106(15):6099–104. https://doi.org/10.1073/pnas.0901506106
PMID: 19332801

PLOS ONE | https://doi.org/10.1371/journal.pone.0261775 January 20, 2022

21 / 24

PLOS ONE

Phase 1 trial of griffithsin formulated in a carrageenan vaginal gel

21.

Garg AB, Nuttall J, Romano J. The future of HIV microbicides: challenges and opportunities. Antivir
Chem Chemother. 2009; 19(4):143–50. https://doi.org/10.1177/095632020901900401 PMID:
19374141

22.

Kreiss J, Ngugi E, Holmes K, Ndinya-Achola J, Waiyaki P, Roberts PL, et al. Efficacy of nonoxynol 9
contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes. JAMA.
1992; 268(4):477–82. PMID: 1320133

23.

Roddy RE, Zekeng L, Ryan KA, Tamoufe U, Weir SS, Wong EL. A controlled trial of nonoxynol 9 film to
reduce male-to-female transmission of sexually transmitted diseases. N Engl J Med. 1998; 339(8):504–
10. https://doi.org/10.1056/NEJM199808203390803 PMID: 9709043

24.

Van Damme L, Ramjee G, Alary M, Vuylsteke B, Chandeying V, Rees H, et al. Effectiveness of COL1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled
trial. Lancet. 2002; 360(9338):971–7. https://doi.org/10.1016/s0140-6736(02)11079-8 PMID: 12383665

25.

Abdool Karim SS, Richardson BA, Ramjee G, Hoffman IF, Chirenje ZM, Taha T, et al. Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS. 2011;
25(7):957–66. https://doi.org/10.1097/QAD.0b013e32834541d9 PMID: 21330907

26.

Skoler-Karpoff S, Ramjee G, Ahmed K, Altini L, Plagianos MG, Friedland B, et al. Efficacy of Carraguard
for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled
trial. Lancet. 2008; 372(9654):1977–87. https://doi.org/10.1016/S0140-6736(08)61842-5 PMID:
19059048

27.

Halpern V, Ogunsola F, Obunge O, Wang CH, Onyejepu N, Oduyebo O, et al. Effectiveness of cellulose
sulfate vaginal gel for the prevention of HIV infection: results of a Phase III trial in Nigeria. PLoS One.
2008; 3(11):e3784. https://doi.org/10.1371/journal.pone.0003784 PMID: 19023429

28.

Van Damme L, Govinden R, Mirembe FM, Guedou F, Solomon S, Becker ML, et al. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med. 2008; 359
(5):463–72. https://doi.org/10.1056/NEJMoa0707957 PMID: 18669425

29.

McCormack S, Ramjee G, Kamali A, Rees H, Crook AM, Gafos M, et al. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet. 2010; 376(9749):1329–37. https://doi.org/10.1016/S0140-6736
(10)61086-0 PMID: 20851460

30.

Alexandre KB, Gray ES, Pantophlet R, Moore PL, McMahon JB, Chakauya E, et al. Binding of the mannose-specific lectin, griffithsin, to HIV-1 gp120 exposes the CD4-binding site. J Virol. 2011; 85
(17):9039–50. https://doi.org/10.1128/JVI.02675-10 PMID: 21697467

31.

Mori T, O’Keefe BR, Sowder RC 2nd, Bringans S, Gardella R, Berg S, et al. Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp. J Biol Chem. 2005;
280(10):9345–53. https://doi.org/10.1074/jbc.M411122200 PMID: 15613479

32.

Fernandez-Romero JA, Deal C, Herold BC, Schiller J, Patton D, Zydowsky T, et al. Multipurpose prevention technologies: the future of HIV and STI protection. Trends Microbiol. 2015; 23(7):429–36.
https://doi.org/10.1016/j.tim.2015.02.006 PMID: 25759332

33.

Nixon B, Stefanidou M, Mesquita PM, Fakioglu E, Segarra T, Rohan L, et al. Griffithsin protects mice
from genital herpes by preventing cell-to-cell spread. J Virol. 2013; 87(11):6257–69. https://doi.org/10.
1128/JVI.00012-13 PMID: 23536670

34.

Levendosky K, Mizenina O, Martinelli E, Jean-Pierre N, Kizima L, Rodriguez A, et al. Griffithsin and Carrageenan Combination To Target Herpes Simplex Virus 2 and Human Papillomavirus. Antimicrob
Agents Chemother. 2015; 59(12):7290–8. https://doi.org/10.1128/AAC.01816-15 PMID: 26369967

35.

Politch JA, Cu-Uvin S, Moench TR, Tashima KT, Marathe JG, Guthrie KM, et al. Safety, acceptability,
and pharmacokinetics of a monoclonal antibody-based vaginal multipurpose prevention film (MB66): A
Phase I randomized trial. PLoS Med. 2021; 18(2):e1003495. https://doi.org/10.1371/journal.pmed.
1003495 PMID: 33534791

36.

Morris GC, Wiggins RC, Woodhall SC, Bland JM, Taylor CR, Jespers V, et al. MABGEL 1: first phase 1
trial of the anti-HIV-1 monoclonal antibodies 2F5, 4E10 and 2G12 as a vaginal microbicide. PLoS One.
2014; 9(12):e116153. https://doi.org/10.1371/journal.pone.0116153 PMID: 25546420

37.

https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf.

38.

Wallace A, Thorn M, Maguire RA, Sudol KM, Phillips DM. Assay for establishing whether microbicide
applicators have been exposed to the vagina. Sex Transm Dis. 2004; 31(8):465–8. https://doi.org/10.
1097/01.olq.0000135986.35216.ba PMID: 15273578

39.

Wallace AR, Teitelbaum A, Wan L, Mulima MG, Guichard L, Skoler S, et al. Determining the feasibility
of utilizing the microbicide applicator compliance assay for use in clinical trials. Contraception. 2007; 76
(1):53–6. https://doi.org/10.1016/j.contraception.2006.10.012 PMID: 17586138

PLOS ONE | https://doi.org/10.1371/journal.pone.0261775 January 20, 2022

22 / 24

PLOS ONE

Phase 1 trial of griffithsin formulated in a carrageenan vaginal gel

40.

Thurman AR, Kimble T, Herold B, Mesquita PM, Fichorova RN, Dawood HY, et al. Bacterial Vaginosis
and Subclinical Markers of Genital Tract Inflammation and Mucosal Immunity. AIDS Res Hum Retroviruses. 2015; 31(11):1139–52. https://doi.org/10.1089/aid.2015.0006 PMID: 26204200

41.

Fichorova RN. Guiding the vaginal microbicide trials with biomarkers of inflammation. J Acquir Immune
Defic Syndr. 2004; 37 Suppl 3:S184–93. PMID: 16419271

42.

Tate J, Ward G. Interferences in immunoassay. Clin Biochem Rev. 2004; 25(2):105–20. PMID:
18458713

43.

Villegas G, Calenda G, Zhang S, Mizenina O, Kleinbeck K, Cooney ML, et al. In Vitro Exposure to PC1005 and Cervicovaginal Lavage Fluid from Women Vaginally Administered PC-1005 Inhibits HIV-1
and HSV-2 Infection in Human Cervical Mucosa. Antimicrob Agents Chemother. 2016; 60(9):5459–66.
https://doi.org/10.1128/AAC.00392-16 PMID: 27381393

44.

Mukhopadhyay S, Liang Y, Hur H, Villegas G, Calenda G, Reis A, et al. Comparative transcriptome
analysis of the human endocervix and ectocervix during the proliferative and secretory phases of the
menstrual cycle. Sci Rep. 2019; 9(1):13494. https://doi.org/10.1038/s41598-019-49647-3 PMID:
31530865

45.

Begay O, Jean-Pierre N, Abraham CJ, Chudolij A, Seidor S, Rodriguez A, et al. Identification of personal lubricants that can cause rectal epithelial cell damage and enhance HIV type 1 replication in vitro.
AIDS Res Hum Retroviruses. 2011; 27(9):1019–24. https://doi.org/10.1089/AID.2010.0252 PMID:
21309617

46.

Kizima L, Rodriguez A, Kenney J, Derby N, Mizenina O, Menon R, et al. A potent combination microbicide that targets SHIV-RT, HSV-2 and HPV. PLoS One. 2014; 9(4):e94547. https://doi.org/10.1371/
journal.pone.0094547 PMID: 24740100

47.

Rodriguez A, Kleinbeck K, Mizenina O, Kizima L, Levendosky K, Jean-Pierre N, et al. In vitro and in vivo
evaluation of two carrageenan-based formulations to prevent HPV acquisition. Antiviral Res. 2014;
108:88–93. https://doi.org/10.1016/j.antiviral.2014.05.018 PMID: 24909570

48.

Barnable P, Calenda G, Ouattara L, Gettie A, Blanchard J, Jean-Pierre N, et al. A MIV-150/zinc acetate
gel inhibits SHIV-RT infection in macaque vaginal explants. PLoS One. 2014; 9(9):e108109. https://doi.
org/10.1371/journal.pone.0108109 PMID: 25259616

49.

Richardson-Harman N, Lackman-Smith C, Fletcher PS, Anton PA, Bremer JW, Dezzutti CS, et al. Multisite comparison of anti-human immunodeficiency virus microbicide activity in explant assays using a
novel endpoint analysis. J Clin Microbiol. 2009; 47(11):3530–9. https://doi.org/10.1128/JCM.00673-09
PMID: 19726602

50.

Aravantinou M, Singer R, Derby N, Calenda G, Mawson P, Abraham CJ, et al. The nonnucleoside
reverse transcription inhibitor MIV-160 delivered from an intravaginal ring, but not from a carrageenan
gel, protects against simian/human immunodeficiency virus-RT Infection. AIDS Res Hum Retroviruses.
2012; 28(11):1467–75. https://doi.org/10.1089/aid.2012.0080 PMID: 22816564

51.

Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression
analysis of digital gene expression data. Bioinformatics. 2010; 26(1):139–40. https://doi.org/10.1093/
bioinformatics/btp616 PMID: 19910308

52.

Mauck C, Chen PL, Morrison CS, Fichorova RN, Kwok C, Chipato T, et al. Biomarkers of Cervical
Inflammation and Immunity Associated with Cervical Shedding of HIV-1. AIDS Res Hum Retroviruses.
2016; 32(5):443–51. https://doi.org/10.1089/AID.2015.0088 PMID: 26650885

53.

Schwartz JL, Mauck C, Lai JJ, Creinin MD, Brache V, Ballagh SA, et al. Fourteen-day safety and
acceptability study of 6% cellulose sulfate gel: a randomized double-blind Phase I safety study. Contraception. 2006; 74(2):133–40. https://doi.org/10.1016/j.contraception.2006.02.008 PMID: 16860051

54.

Derby N, Lal M, Aravantinou M, Kizima L, Barnable P, Rodriguez A, et al. Griffithsin carrageenan fast
dissolving inserts prevent SHIV HSV-2 and HPV infections in vivo. Nat Commun. 2018; 9(1):3881.
https://doi.org/10.1038/s41467-018-06349-0 PMID: 30250170

55.

Li Q, Estes JD, Schlievert PM, Duan L, Brosnahan AJ, Southern PJ, et al. Glycerol monolaurate prevents mucosal SIV transmission. Nature. 2009; 458(7241):1034–8. https://doi.org/10.1038/
nature07831 PMID: 19262509

56.

Smith-McCune K, Chen JC, Greenblatt RM, Shanmugasundaram U, Shacklett BL, Hilton JF, et al.
Unexpected Inflammatory Effects of Intravaginal Gels (Universal Placebo Gel and Nonoxynol-9) on the
Upper Female Reproductive Tract: A Randomized Crossover Study. PLoS One. 2015; 10(7):
e0129769. https://doi.org/10.1371/journal.pone.0129769 PMID: 26177352

57.

Schall TJ, Bacon K, Toy KJ, Goeddel DV. Selective attraction of monocytes and T lymphocytes of the
memory phenotype by cytokine RANTES. Nature. 1990; 347(6294):669–71. https://doi.org/10.1038/
347669a0 PMID: 1699135

PLOS ONE | https://doi.org/10.1371/journal.pone.0261775 January 20, 2022

23 / 24

PLOS ONE

Phase 1 trial of griffithsin formulated in a carrageenan vaginal gel

58.

Taub DD, Lloyd AR, Wang JM, Oppenheim JJ, Kelvin DJ. The effects of human recombinant MIP-1
alpha, MIP-1 beta, and RANTES on the chemotaxis and adhesion of T cell subsets. Adv Exp Med Biol.
1993; 351:139–46. https://doi.org/10.1007/978-1-4615-2952-1_15 PMID: 7524282

59.

Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP-1
alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science. 1995;
270(5243):1811–5. https://doi.org/10.1126/science.270.5243.1811 PMID: 8525373

60.

Ozdemir V, Endrenyi L. A New Approach to Measure Adherence to Medicines Using Biomarkers and
Sensors. OMICS. 2019; 23(7):334–7. https://doi.org/10.1089/omi.2019.0092 PMID: 31199695

61.

Haaland RE, Chaowanachan T, Evans-Strickfaden T, van de Wijgert JH, Kilmarx PH, McLean CA,
et al. Carrageenan-based gel retains limited anti-HIV-1 activity 8–24 hours after vaginal application by
HIV-infected Thai women enrolled in a phase I safety trial. J Acquir Immune Defic Syndr. 2012; 61(5):
e71–3. https://doi.org/10.1097/QAI.0b013e318271c8f9 PMID: 23183152

PLOS ONE | https://doi.org/10.1371/journal.pone.0261775 January 20, 2022

24 / 24

